The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The mechanism of action of MF59 – An innately attractive adjuvant formulation
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
Self-citationCalabro, S., Tortoli, M., Baudner, B. C., Pacitto, A., Cortese, M., O’Hagan, D. T., De Gregorio, E., Seubert, A., & Wack, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.090 · Cited by 433
Self-citationSeubert, A., Monaci, E., Pizza, M., O’Hagan, D. T., & Wack, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5402 · Cited by 430
Self-citationNew adjuvants for human vaccines
Mbow, M. L., De Gregorio, E., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 406
Self-citationOil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children
Vesikari, T., Knuf, M., Wutzler, P., Karvonen, A., Kieninger-Baum, D., Schmitt, H.-J., Baehner, F., Borkowski, A., Tsai, T. F., & Clemens, R. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010331 · Cited by 317
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
Self-citationO’Hagan, D. T. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.699 · Cited by 282
Self-citationThe path to a successful vaccine adjuvant – ‘The long and winding road’
O’Hagan, D. T., & De Gregorio, E. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.009 · Cited by 274
Self-citationKhurana, S., Chearwae, W., Castellino, F., Manischewitz, J., King, L. R., Honorkiewicz, A., Rock, M. T., Edwards, K. M., Del Giudice, G., Rappuoli, R., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000624 · Cited by 268
Galli, G., Hancock, K., Hoschler, K., DeVos, J., Praus, M., Bardelli, M., Malzone, C., Castellino, F., Gentile, C., McNally, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903181106 · Cited by 263
Cited by
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Immunosenescence and human vaccine immune responses
Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0164-9 · Cited by 530
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, N. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1213632 · Cited by 516
The how’s and what’s of vaccine reactogenicity
Hervé, C., Laupèze, B., Del Giudice, G., Didierlaurent, A. M., & Tavares Da Silva, F. (2019) · npj Vaccines · doi:10.1038/s41541-019-0132-6 · Cited by 513
Metadata
- Authors
- O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 30
- Issue
- 29
- Pages
- 4341-4348
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W1979195886
- Cited by
- 488
- References
- 29
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The mechanism of action of MF59 – An innately attractive adjuvant formulation. https://app.cochat.ai/papers/10.1016/j.vaccine.2011.09.061
- The paper
- O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012). The mechanism of action of MF59 – An innately attractive adjuvant formulation. Vaccine. https://doi.org/10.1016/j.vaccine.2011.09.061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.